LuciErlo — Erlotinib 150 mg, 30 pcs, Lucius

LuciErlo — Erlotinib Tablets 150 mg, 30 Tablets

Product code: 500

4470₴ 4872₴ -8% On order · from 10 days

Analogues

Erlocip Erlonat LuciErlo
1
Active ingredient
Dosage
150 mg
Dosage form Tablets
Tablets per pack 30

LuciErlo is a targeted antineoplastic agent belonging to the tyrosine kinase inhibitor (TKI) class, indicated for the treatment of non-small cell lung cancer and pancreatic cancer. The active pharmaceutical ingredient is erlotinib at a strength of 150 mg supplied as film-coated oral tablets (Erlotinib Tablets 150 mg). The product is developed and manufactured by Lucius Pharmaceuticals.

Erlotinib is a selective, reversible inhibitor of the epidermal growth factor receptor (EGFR - HER1) tyrosine kinase. Blocking EGFR kinase activity inhibits proliferation and induces apoptosis in tumor cells expressing EGFR. Erlotinib is highly effective in non-small cell lung cancer patients harboring activating EGFR mutations and is also indicated in combination with gemcitabine for the treatment of metastatic pancreatic cancer.

Supplied in a package containing 30 tablets of 150 mg (a full 1-month treatment course). Intended exclusively for oral administration under the strict supervision of an oncologist.

Key Clinical Features and Advantages of LuciErlo 150 mg:

  • ✅ Selective EGFR Inhibition: Targeted suppression of epidermal growth factor receptor kinase activity.
  • ✅ Proven Efficacy: High therapeutic activity in EGFR-mutated non-small cell lung cancer and pancreatic cancer.
  • ✅ Convenient Oral Administration: Taken orally once daily on an empty stomach.
  • ✅ Enhanced Quality of Life: Provides disease control with significantly lower systemic toxicity compared to conventional chemotherapy.
  • ✅ Lucius Pharmaceuticals Standards: High-quality, accessible generic alternative to the originator product (Tarceva).

LuciErlo is supplied as film-coated tablets for oral administration.

Qualitative and Quantitative Composition per Tablet:

  • Active Ingredient: Erlotinib (as erlotinib hydrochloride) — 150 mg.
  • Excipients: Lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, magnesium stearate. Coating: hypromellose, hydroxypropyl cellulose, macrogol, titanium dioxide.

Packaging and Presentation: Film-coated tablets, 150 mg strength. Each package contains 30 tablets along with prescribing information. Labeled with LuciErlo (Erlotinib Tablets 150 mg) and Lucius Pharmaceuticals corporate graphics.

Pharmacodynamics:
Erlotinib is a potent inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. EGFR is expressed on the cell surface of both normal and tumor cells. Erlotinib competitively inhibits intracellular EGFR phosphorylation, resulting in the blockade of signal transduction pathways that stimulate tumor cell growth, survival, and metastasis.

Pharmacokinetics:

  • Absorption: Following oral administration, erlotinib absorption is relatively slow; peak plasma concentration (Tmax) is achieved within approximately 4 hours. Food intake significantly increases bioavailability (must always be taken strictly on an empty stomach!).
  • Distribution: Plasma protein binding is approximately 93% (bound primarily to albumin and alpha-1-acid glycoprotein).
  • Metabolism: Metabolized in the liver via cytochrome P450 enzymes, predominantly CYP3A4 and minor contributions from CYP1A2.
  • Elimination: Excreted predominantly via feces (approx. 83% as metabolites) and renally (approx. 8%). Terminal elimination half-life (T1/2) averages approximately 36 hours.

LuciErlo is indicated in adult patients for:

  • Non-Small Cell Lung Cancer (NSCLC): Treatment of patients with locally advanced or metastatic non-small cell lung cancer harboring activating EGFR mutations as first-line therapy or following failure of prior chemotherapy.
  • Pancreatic Cancer: In combination with gemcitabine for the treatment of patients with metastatic pancreatic cancer.

LuciErlo is administered orally once daily every day at approximately the same time.

Dosing Regimen:

  • For NSCLC: Recommended dose is 150 mg once daily.
  • For Pancreatic Cancer: Recommended dose is 100 mg once daily in combination with gemcitabine.

Administration Guidelines:
Tablets must be taken on an empty stomach — at least 1 hour before or 2 hours after a meal. Swallow tablets whole with water; do not break or crush.

Administration of LuciErlo is contraindicated in:

  • Hypersensitivity: Known hypersensitivity to erlotinib or any excipient (including lactose intolerance).
  • Pregnancy and Lactation: Contraindicated during pregnancy and breastfeeding.
  • Pediatric Population: Safety and efficacy in patients under 18 years have not been established.
  • Severe Hepatic or Renal Impairment: Pronounced liver or kidney dysfunction.

Erlotinib is metabolized by hepatic enzymes (predominantly CYP3A4):

  • Strong CYP3A4 Inducers (rifampicin, phenytoin, carbamazepine, barbiturates, St. John's Wort): Significantly decrease erlotinib blood concentrations and reduce antitumor efficacy. Avoid concurrent use.
  • Strong CYP3A4 Inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice): Increase erlotinib plasma concentrations and toxicity risks.
  • Gastric pH-Altering Agents (proton pump inhibitors, antacids): May reduce erlotinib bioavailability and efficacy.

Pregnancy:
LuciErlo is contraindicated during pregnancy. Erlotinib may cause fetal harm and embryotoxicity. Females of reproductive potential must utilize effective reliable contraception during treatment and for at least 2 weeks following the final dose.

Lactation:
Excretion of erlotinib into human breast milk has been demonstrated. Breastfeeding must be discontinued during treatment.

The most frequent and clinically significant adverse reactions include:

  • Dermatologic Reactions (Very Common): Acneiform rash (primarily on the face, neck, and chest), dry skin, pruritus, skin fissures, paronychia.
  • Gastrointestinal Tract: Diarrhea (requires prompt loperamide therapy and hydration), nausea, vomiting, stomatitis, anorexia.
  • General Disorders: Fatigue, asthenia, dyspnea, cough.
  • Laboratory Abnormalities: Asymptomatic elevations in liver transaminases (ALT, AST) and bilirubin.
  • Rare but Severe Effects: Interstitial lung disease (pneumonitis), gastrointestinal perforation, severe cutaneous reactions.

Symptoms:
Symptoms of erlotinib overdose include exacerbation of adverse reactions: severe diarrhea, skin rashes, and elevated liver function test parameters.

Treatment:
No specific antidote exists. In case of overdose, withhold treatment and initiate supportive and symptomatic care.

Storage Requirements for LuciErlo 150 mg:

  • 🌡️ Temperature Range: Store in original packaging in a dry place protected from light at temperatures below 30 °C.
  • 👶 Safety Precautions: Keep strictly out of reach of children (cytotoxic antineoplastic agent).
  • ⏳ Shelf Life: Stated on carton and blister pack. Don't use past expiration date. Prescription-only oncology medicine.

To verify authenticity of genuine LuciErlo 150 mg manufactured by Lucius Pharmaceuticals, inspect the following security and visual features:

  • ✅ Security Hologram & Scratch Code: Outer carton features an official Lucius Pharmaceuticals anti-counterfeit holographic seal with a scratch-off verification code for online validation via the manufacturer's official portal.
  • ✅ Corporate Branding: High-resolution printing displaying Lucius Pharmaceuticals graphics, Erlotinib Tablets 150 mg, and 30 Tablets count.
  • ✅ Factory Markings: Clearly printed Batch No., Mfg. Date, and Exp. Date matching across outer packaging and internal blister packs.
  • ✅ Prescribing Information: Includes an official product leaflet inside the outer carton.
On order · from 10 days
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 14.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00